208 related articles for article (PubMed ID: 34079795)
1. Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.
Kuang Z; Li X; Liu R; Chen S; Tu J
Front Cell Dev Biol; 2021; 9():648856. PubMed ID: 34079795
[TBL] [Abstract][Full Text] [Related]
2. The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
Wang W; Xu SW; Teng Y; Zhu M; Guo QY; Wang YW; Mao XL; Li SW; Luo WD
Front Cell Dev Biol; 2021; 9():779123. PubMed ID: 34805183
[No Abstract] [Full Text] [Related]
3. A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma.
Wu Z; Guan Q; Han X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Wang X; Zhang H
Aging (Albany NY); 2021 Oct; 13(19):22947-22962. PubMed ID: 34610582
[TBL] [Abstract][Full Text] [Related]
4. Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle.
Zhuang X; Liu B; Long J; Wang H; Yu J; Ji X; Li J; Zhu N; Li L; Chen Y; Liu Z; Zhao S
Clin Transl Oncol; 2024 Apr; 26(4):936-950. PubMed ID: 37783922
[TBL] [Abstract][Full Text] [Related]
5. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
9. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract][Full Text] [Related]
11. Integrative analysis of a necroptosis-related gene signature of clinical value and heterogeneity in diffuse large B cell lymphoma.
Pan YB; Wang W; Cai HK; Zhang J; Teng Y; Xue J; Zhu M; Luo WD
Front Genet; 2022; 13():911443. PubMed ID: 36035126
[No Abstract] [Full Text] [Related]
12. A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma.
Zhou H; Zheng C; Huang DS
PeerJ; 2020; 8():e9658. PubMed ID: 32844062
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma.
Liu C; Liu L
Front Genet; 2022; 13():1037716. PubMed ID: 36313435
[No Abstract] [Full Text] [Related]
14. Identification and Development of a 4-Gene Ferroptosis Signature Predicting Overall Survival for Diffuse Large B-Cell Lymphoma.
Wu H; Zhang J; Fu L; Wu R; Gu Z; Yin C; He K
Technol Cancer Res Treat; 2023; 22():15330338221147772. PubMed ID: 36762399
[No Abstract] [Full Text] [Related]
15. Development of a Reproducible Prognostic Gene Signature to Predict the Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma.
Zamani-Ahmadmahmudi M; Nassiri SM
Sci Rep; 2019 Aug; 9(1):12198. PubMed ID: 31434961
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes.
Pan T; He Y; Chen H; Pei J; Li Y; Zeng R; Xia J; Zuo Y; Qin L; Chen S; Xiao L; Zhou H
Front Oncol; 2021; 11():614211. PubMed ID: 33692952
[TBL] [Abstract][Full Text] [Related]
17. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
Xiong D; Wei X; Huang W; Zheng J; Feng R
Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
[TBL] [Abstract][Full Text] [Related]
18. The expression landscape of cachexia-inducing factors in human cancers.
Freire PP; Fernandez GJ; de Moraes D; Cury SS; Dal Pai-Silva M; Dos Reis PP; Rogatto SR; Carvalho RF
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):947-961. PubMed ID: 32125790
[TBL] [Abstract][Full Text] [Related]
19. Expression of N
Xie Z; Li M; Hong H; Xu Q; He Z; Peng Z
Bioengineered; 2021 Dec; 12(1):6115-6133. PubMed ID: 34482808
[TBL] [Abstract][Full Text] [Related]
20. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
